rs1063537 — ADIPOQ

ADIPOQ +3228 C/T — The 3'UTR Rheostat of Adiponectin Output

Adiponectin is the most abundant hormone secreted by fat tissue, yet its effects run counter to what you might expect: despite originating in adipose cells, it works against the pathological consequences of excess fat. It sensitizes muscle and liver to insulin, suppresses inflammatory cytokines, and protects blood vessel walls from the calcification that drives atherosclerosis. Circulating adiponectin levels vary 10-fold between individuals, and much of that variation is genetic. The rs1063537 variant (+3228 C/T) sits at position 186,856,286 on chromosome 3 within the 3' untranslated region (3'UTR) of ADIPOQ — a stretch of RNA sequence that, while not coding for protein, acts as a control panel for mRNA stability and translational efficiency¹¹ control panel for mRNA stability and translational efficiency
the 3'UTR contains binding sites for RNA-binding proteins and microRNAs that regulate how much mRNA is degraded versus translated into protein; small sequence changes here can shift the steady-state amount of adiponectin protein produced by adipocytes.

The Mechanism

The ADIPOQ gene lies on the plus strand of chromosome 3 and its 3'UTR is a regulatory hub. Adipocytes express multiple microRNAs²² microRNAs
small non-coding RNA molecules that bind to the 3'UTR of target mRNAs and typically reduce their translation or promote their degradation that target ADIPOQ mRNA, including miR-378 and miR-221. A C-to-T change at the +3228 position alters the local RNA secondary structure and microRNA binding affinity, modulating how quickly the transcript is cleared. The net result: C allele carriers have lower average circulating adiponectin than T allele carriers. In the Chingford cohort³³ In the Chingford cohort
Kyriakou et al. 2008, two female cohorts totalling >2,400 women, TT homozygotes had mean fasting adiponectin of 24.87 μg/mL versus 19.90 μg/mL in CC homozygotes — a 25% difference driven by a single nucleotide change in an untranslated region.

The C allele at rs1063537 is the GRCh38 reference allele and is far more common globally (~79% CC genotype, ~12% T allele frequency in Europeans, ~28% in East Asians). Because the common allele is the one that reduces adiponectin, the majority of the population operates at a mild adiponectin disadvantage relative to the rare T homozygotes.

The Evidence

Fasting adiponectin levels: The clearest functional signal for rs1063537 comes from Kyriakou et al. 2008⁴⁴ Kyriakou et al. 2008
Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female populations and effects of SNPs on promoter activity. J Hum Genet. 2008, which showed additive association (p=0.01) with serum adiponectin in 800 UK women, where each T allele added approximately 2–2.5 μg/mL to circulating levels. This replication in a second cohort of 1,629 women was not significant, suggesting a modest effect that requires large samples.

Type 2 diabetes: A Han Chinese case-control study of 768 subjects by Chung et al.⁵⁵ Chung et al.
Association of four insulin resistance genes with type 2 diabetes mellitus and hypertension in the Chinese Han population. Mol Biol Rep. 2014 found the T allele was protective against T2DM: allele frequency was 26.8% in T2DM cases versus 36.3% in controls (OR=0.64, 95% CI 0.45–0.91, p=0.014). This is consistent with the T allele's association with higher adiponectin, which enhances insulin sensitivity.

Coronary artery calcification: In the Multi-Ethnic Study of Atherosclerosis (MESA)⁶⁶ Multi-Ethnic Study of Atherosclerosis (MESA)
Associations of SNPs in ADIPOQ and subclinical cardiovascular disease. Atherosclerosis. 2012 — 712 African American participants — the AG/AA genotypes of rs1063537 (note: the study used a complementary notation for the same variant; the C allele corresponds to the major G in that encoding) were associated with a 35% greater coronary artery calcification (CAC) prevalence (PR=1.35–1.39, p=0.0005). This finding did not replicate in non-African ancestry groups, and rs1063537 was in high LD with the neighboring rs1063539 (r²=0.90 in African Americans), suggesting the signal may tag a haplotype specific to African ancestral populations.

Diabetic nephropathy: A Taiwanese longitudinal study by Lin et al. 2014⁷⁷ Lin et al. 2014
Adiponectin gene (ADIPOQ) polymorphisms correlate with the progression of nephropathy in Taiwanese male patients with type 2 diabetes. Diabetes Res Clin Pract. 2014 followed 566 T2DM patients with normoalbuminuria over six years. Males carrying the CC genotype had HR=1.89 for nephropathy progression (vs CT+TT, 95% CI 1.15–3.11, p=0.013). A more recent study of 538 Chinese Han T2DM patients found TT genotype carriers had a 2.47-fold higher risk of macroalbuminuria versus CC (p=0.016) — an apparently paradoxical finding that may reflect the nonlinear biology of adiponectin in established kidney disease, where adiponectin's anti-inflammatory signaling in the renal cortex may be altered by chronic inflammation.

Obstructive sleep apnea: Chen et al. 2019⁸⁸ Chen et al. 2019
ADIPOQ rs1063537 and obstructive sleep apnoea in Chinese Han adults. Targeted sequencing. OMICS. 2019 found CT/TT genotypes associated with 2.155-fold increased OSA risk (95% CI 1.149–4.041, p=0.017), with significantly higher apnea-hypopnea index (23.20 vs 17.15 events/hour, p=0.004). The mechanism may involve adiponectin's modulation of upper airway muscle tone and inflammation, though this finding requires replication.

Practical Implications

Low circulating adiponectin is a well-established driver of insulin resistance and cardiometabolic risk. For CC carriers, the primary levers are lifestyle factors known to upregulate ADIPOQ transcription and secretion: omega-3 fatty acids activate PPARγ⁹⁹ PPARγ
peroxisome proliferator-activated receptor gamma — the master regulator of adipocyte gene expression that directly drives ADIPOQ transcription, weight loss disproportionately raises adiponectin relative to other adipokines, and moderate caloric restriction upregulates adiponectin secretion. Monitoring fasting insulin and HOMA-IR provides a functional readout of whether adiponectin signaling is adequate.

For individuals with established T2DM, regular monitoring of urine albumin-to-creatinine ratio (uACR) is warranted given the nephropathy progression risk documented in this population — particularly in males, where the sex-specific HR=1.89 signal was found.

Interactions

rs1063537 lies at the 3' end of ADIPOQ within a block of variants that includes rs1063539 (high LD in African Americans, r²=0.90). The larger ADIPOQ haplotype context is defined by rs17300539 (−11391G>A promoter), rs182052 (−10066A>G intron), rs2241766 (+45T>G exon 2), and rs1501299 (+276G>T intron 2) — all already profiled in GeneOps. Together these variants define six common ADIPOQ haplotypes that explain substantially more variance in circulating adiponectin than any single SNP alone. Individuals carrying the CC genotype at rs1063537 plus the risk alleles at rs2241766 (G) and rs182052 (A) may face compounded reduction in adiponectin output via convergent transcriptional, post-transcriptional, and translational mechanisms.